18F-fluciclovine PET is approved for prostate cancer recurrence imaging. According to the
radiopharmaceutical package insert, only 3% of the tracer is expected to be excreted in the …

18F-fluciclovine is a Food and Drug Administration–approved PET tracer indicated for
patients suspected to have recurrent prostate cancer based on a prostate-specific antigen …

Abstract 18 F-Fluciclovine PET/CT has become a common diagnostic imaging study used in
the evaluation of biochemical recurrence in prostate cancer since its approval in 2016. We …

Forced diuresis may improve readability of 2-(3-(1-carboxy-5-[(6-[18 F] fluoro-pyridine-3-
carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid (18 F-DCFPyL) PET/computed …

1228 Introduction: Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous
malignancy among men in the United States (US) representing 9.6% of all new US cancer …

Background A systematic literature review of the performance of 18Fluorine-fluciclovine
PET/CT for imaging of men with recurrent prostate cancer was performed. Methods Scientific …

3042 Introduction: 18 F-fluciclovine, a synthetic amino acid approved for assessment of
biochemically recurrent prostate cancer (BCR PCa), has rapid kinetics and was shown to …

We evaluated 18F-fluciclovine uptake parameters that correlate with true positivity for local
recurrence in non–prostatectomy-treated patients. Methods: Twenty-one patients (prostate …

1470 Objectives: To evaluate the factors influencing the positivity rate of commercial 18 F-
fluciclovine positron emission tomography/computed tomography (PET/CT) in clinical …

The purpose of this study was to assess the feasibility of selective pelvic PET/CT with
retrograde bladder irrigation in evaluating pelvic pathologies. Methods: Thirty-eight patients …